These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 2942099

  • 41. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.
    Hooper DC, Wolfson JS.
    Antimicrob Agents Chemother; 1985 Nov; 28(5):716-21. PubMed ID: 2936302
    [No Abstract] [Full Text] [Related]

  • 42. In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.
    Wise R, Andrews JM, Danks G.
    J Antimicrob Chemother; 1984 Mar; 13(3):237-44. PubMed ID: 6586712
    [Abstract] [Full Text] [Related]

  • 43. Comparison of the antibacterial in vitro and in vivo activity of ofloxacin (HOE 280 DL 8280) and nalidixic acid analogues.
    Seibert G, Limbert M, Klesel N.
    Eur J Clin Microbiol; 1983 Dec; 2(6):548-53. PubMed ID: 6230226
    [Abstract] [Full Text] [Related]

  • 44. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
    Kresken M, Wiedemann B.
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
    [Abstract] [Full Text] [Related]

  • 45. [Fluoroquinolones].
    Baykal M, Akalin E.
    Mikrobiyol Bul; 1987 Apr; 21(2):151-7. PubMed ID: 3482120
    [Abstract] [Full Text] [Related]

  • 46. In vitro evaluation of E-4695, a new fluoro-naphthyridine.
    Jones RN.
    Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):188-94. PubMed ID: 1327787
    [Abstract] [Full Text] [Related]

  • 47. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH.
    Chemotherapy; 1985 Feb; 31(1):34-9. PubMed ID: 3156026
    [Abstract] [Full Text] [Related]

  • 48. Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates.
    Forsgren A.
    Scand J Infect Dis; 1985 Feb; 17(1):91-4. PubMed ID: 3158070
    [Abstract] [Full Text] [Related]

  • 49. The in-vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1984 Apr; 13(4):325-31. PubMed ID: 6233249
    [Abstract] [Full Text] [Related]

  • 50. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI, Dabbs DJ, Spencer RC.
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [Abstract] [Full Text] [Related]

  • 51. Comparative in vitro activity of ciprofloxacin, ofloxacin and pefloxacin against resistant clinical isolates.
    Periti P, Mazzei T, Nicoletti P.
    Chemioterapia; 1987 Apr; 6(2):75-8. PubMed ID: 3474081
    [Abstract] [Full Text] [Related]

  • 52. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA, Cuffini AM, Tullio V, Savoia D, Cavallo GP.
    G Batteriol Virol Immunol; 1986 Apr; 79(1-6):85-97. PubMed ID: 3479370
    [Abstract] [Full Text] [Related]

  • 53. Antibacterial activity of NM394, the active form of prodrug NM441, a new quinolone.
    Yoshida T, Mitsuhashi S.
    Antimicrob Agents Chemother; 1993 Apr; 37(4):793-800. PubMed ID: 8388199
    [Abstract] [Full Text] [Related]

  • 54. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.
    Chin NX, Neu HC.
    Antimicrob Agents Chemother; 1984 Mar; 25(3):319-26. PubMed ID: 6232895
    [Abstract] [Full Text] [Related]

  • 55. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J, Le Noc P, Bryskier A, Robert J.
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [Abstract] [Full Text] [Related]

  • 56. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL, Fuchs PC.
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [Abstract] [Full Text] [Related]

  • 57. Proposed criteria for interpretation of susceptibilities of strains of Neisseria gonorrhoeae to ciprofloxacin, ofloxacin, enoxacin, lomefloxacin, and norfloxacin.
    Knapp JS, Hale JA, Neal SW, Wintersheid K, Rice RJ, Whittington WL.
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2442-5. PubMed ID: 8585723
    [Abstract] [Full Text] [Related]

  • 58. In vitro activity of the newer quinolones compared with the classic ones and tobramycin.
    Boquet Jiménez E, Dalet Escribá F, Caballé L.
    Infection; 1985 Nov; 13(4):193-6. PubMed ID: 2931382
    [Abstract] [Full Text] [Related]

  • 59. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D, Delisle-Mizon F, Vergez P, Daguet GL.
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [Abstract] [Full Text] [Related]

  • 60. Clinical uses of nalidixic acid analogues: the fluoroquinolones.
    Høiby N.
    Eur J Clin Microbiol; 1986 Apr; 5(2):138-40. PubMed ID: 3013628
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.